Abstract
HIFU has acquired wide acceptance in the few last years due to its minimal invasiveness and high effectiveness in prostate cancer patients' treatment. According to latest data, negative biopsy results are observed in 86.4% of treated patients and biochemical relapse-free survival reaches 77%. Yet, negative biopsy results fail to exclude neither the presence nor elevated subsequent recurrence risk. Morphologic studies show limited ability of common H&E method to detect small cancer focuses after HIFU, so the cancer recurrence is infrequently diagnosed only in subsequent biopsies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
